Clinical experiences with G17DT in gastrointestinal malignancies.
The development of new agents for the treatment of gastrointestinal malignancies is increasing in pace and importance. The discovery of novel targets, namely the epidermal growth factor receptor and vascular endothelial growth factor, have sparked an explosion of new agents being tested in gastrointestinal malignancies. Clearly, novel agents and approaches are required. G17DT is a novel immunoconjugate designed to elicit a humoral response against the N-terminal end of G17 gastrin. In this overview, the authors summarize the clinical research focused on gastrointestinal tract cancers to date. In total, there is a clear signal of efficacy with this compound, although further testing is required in order for this efficacy to be demonstrated in a manner that will support regulatory approval.
He
Aiwu R
AR
Vincent T Lombardi Cancer Research Center, Georgetown University Medical Center, Podium Level, Corridor B, 3800 Reservoir Road, NW Washington, DC 20007, USA. arh29@gunet.georgetown.edu
Marshall
John L
JL
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D005755:Gastrins / Q000276:immunology / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D018796:Immunoconjugates / Q000276:immunology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000639:trends*
D019496:Cancer Vaccines; D005755:Gastrins; D018796:Immunoconjugates; C482698:gastrin immunogen